Author's reply. Saudi J Kidney Dis Transpl. 2015 Mar;26(2):378-9 Authors: Emami Zeydi A, Khezri HD PMID: 25958421 [PubMed - in process]
DR JASON WELLEN (St Louis, MO): Dr Cannon and colleagues have presented a retrospective analysis of United Network for Organ Sharing (UNOS) data comparing the outcomes of kidney transplantation, after a simultaneous liver kidney transplantation (SLK), compared with a matched cohort of kidney transplants. They used UNOS data between 2003 and 2012 in order to incorporate the changes to the Model for End-Stage Liver Disease (MELD) allocation. Their manuscript sought to illustrate the potential lost life years of kidney allografts that are being transplanted as SLKs.
Condition: Transplanted Organ Rejection Intervention: Biological: FCR001 Sponsor: Talaris Therapeutics Inc. Not yet recruiting
The authors of this open access paper review the aging of the kidney and consider the prospects for using factors from young blood as a means of rejuvenation. This is a fairly narrow view, as there are many other approaches that should produce rejuvenation of the aged kidney, ranging from those close to realization, such as senolytic therapies to clear senescent cells, or various approaches to stem cell therapy, to those yet to be achieved, meaning much of the rest of the SENS agenda of rejuvenation biotechnologies to repair the damage that causes aging. Nonetheless, after so many years of trying to persuade the research c...
Discussion Transplantation is not a common problem for primary care physicians but when a child’s disease has progressed to end-stage organ failure, transplantation can be the only treatment available. While the primary care provider usually is not involved in the daily management of patients before, during and after transplantation, they can be involved in many areas. These can include providing appropriate primary and acute care, ordering and obtaining necessary medical tests, medications and equipment, assisting with medical insurance, providing medical history and records to consultants, translating medical infor...
Nature Reviews Nephrology, Published online: 24 June 2019; doi:10.1038/s41581-019-0173-0Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been recommended for the treatment of patients with type 2 diabetes mellitus and cardiovascular disease, heart failure or chronic kidney disease. Findings from recent efficacy and safety trials of empagliflozin in kidney transplant recipients with post-transplantation diabetes are timely, given the elevated cardiovascular risk associated with solid organ transplantation.
This article reviews routine postsurgical intensive care unit management, along with management of complications such as acute kidney injury, atrial arrhythmias, deep vein thrombosis, primary graft dysfunction, hyperammonemia syndrome, and thrombocytopenia. Finally, management of long-term issues, including diabetes mellitus, hypertension, and bronchial stenosis, is discussed.
CONCLUSIONS: Data from our series demonstrate that outcomes and renal function follow up over time were similar among both groups. In expert hands, this altruistic procedure can be performed with a minimally invasive approach without an increased complication rate or compromising renal function in donors. PMID: 31223128 [PubMed - in process]
ConclusionTailoring tacrolimus therapy early post ‐transplant based on CDR is not supported by the findings in this study.This article is protected by copyright. All rights reserved.
Sodium zirconium cyclosilicate effectively treats hyperkalemia in patients receiving hemodialysis for end-stage kidney disease, and no new safety concerns were observed in the phase 3 DIALIZE study.Medscape Medical News
As I begin my term as Chair of the Council on Renal Nutrition, I can ’t help but reflect on my journey to this point. I have been an registered dietitian nutritionist (RDN) for over 35 years and almost 20 of those years have been in the field of Nephrology. In caring for patients across the full spectrum of this specialty, I have worked with dialysis patients, pre -transplant and post-transplant patients, kidney donors, and CKD patients. I am currently employed in a multidisciplinary Chronic Kidney Disease Clinic.